Patent
Micro- and nano-device for cartilage injury detection and treatment
| العنوان: | Micro- and nano-device for cartilage injury detection and treatment |
|---|---|
| Patent Number: | 12201,700 |
| تاريخ النشر: | January 21, 2025 |
| Appl. No: | 15/766039 |
| Application Filed: | October 05, 2016 |
| مستخلص: | The present invention provides targeting probe, imaging probes, and probes for use as a medicament to treat damaged cartilage, where the probe targets injured tissue and can then be imaged and/or release agents to trigger the migration of surrounding chondrocytes from healthy tissue to injured tissue and/or recruit synovial stem cells. |
| Inventors: | Board of Regents, The University of Texas System (Austin, TX, US); Borrelli, Joseph (Dallas, TX, US) |
| Assignees: | Borreli, Joseph (Dallas, TX, US), Board of Regents, The University of Texas System (Austin, TX, US) |
| Claim: | 1. An arthritic cartilage targeting probe comprising: a biocompatible hyaluronic acid polymer crosslinked by a vinyl sulfone to form a crosslinked biopolymer, wherein the biocompatible hyaluronic acid polymer has a molecular weight of 10K to 1.5M and the crosslinking ratio of the biocompatible HA polymer:vinyl sulfone is between 4:1 and 1:4 and the crosslinked biopolymer has a diameter of about 200 to 500 nm to modulate internalization; a ligand in contact with the crosslinked biopolymer, wherein the ligand is hyaluronic acid that interacts with a CD44 receptor, folic acid that interacts with a folate receptor or both; and a detectable tag in contact with the crosslinking agent, first biocompatible polymer, the ligand or a combination thereof, wherein the probe triggers stem cell recruitment, differentiation, and cartilage regeneration. |
| Claim: | 2. A damaged cartilage targeting probe comprising: a biocompatible hyaluronic acid polymer crosslinked by a vinyl sulfone to form a crosslinked biopolymer, wherein the biocompatible hyaluronic acid polymer has a molecular weight of 10K to 1.5M and the crosslinking ratio of the biocompatible HA polymer:vinyl sulfone is between 4:1 and 1:4 and the crosslinked biopolymer has a diameter of about 200 to 500 nm to modulate internalization; a ligand in contact with the crosslinked biopolymer, wherein the ligand interacts with one or more cell surface targets; and a detectable tag in contact with the crosslinking agent, first biocompatible polymer, the ligand or a combination thereof, wherein the probe triggers stem cell recruitment, differentiation, and cartilage regeneration. |
| Claim: | 3. A method for identifying damaged cartilage comprising: providing a damaged cartilage targeting probe that comprises a biocompatible hyaluronic acid polymer crosslinked by a vinyl sulfone crosslinking agent to form a crosslinked biopolymer, wherein the biocompatible hyaluronic acid polymer has a molecular weight of 10K to 1.5M and the crosslinking ratio of the biocompatible polymer:crosslinking agent is between 4:1 and 1:4; wherein the crosslinked biopolymer has a diameter of about 200 to 500 nm to modulate internalization; a ligand in contact with the crosslinked biopolymer, wherein the ligand interacts with one or more cell surface targets; and a detectable tag in contact with the crosslinking agent, first biocompatible polymer, the ligand or a combination thereof; contacting a cartilage suspected of being damaged with the damaged cartilage targeting probe; and detecting the damaged cartilage targeting probe. |
| Claim: | 4. A cartilage targeting probe to treat damaged cartilage by recruiting stem cells, chondrocytes or both to the damaged cartilage, wherein the cartilage targeting probe comprises: a biocompatible hyaluronic acid polymer crosslinked by a vinyl sulfone crosslinking agent to form a crosslinked biopolymer, wherein the biocompatible hyaluronic acid polymer has a molecular weight of 10K to 1.5M and the crosslinking ratio of the biocompatible polymer:crosslinking agent is between 4:1 and 1:4 and the crosslinked biopolymer has a diameter of about 200 to 500 nm to modulate internalization; a ligand in contact with the crosslinked biopolymer, wherein the ligand interacts with one or more cell surface targets; one or more chemokines selected from SDF 1, SDF 1β, Epo, CCL2, CCL16, VEGF, TGF-β1 and TGF-β3, associated with the polymer targeting probe, wherein the one or more chemokines are released to recruit stem cells, chondrocytes or both; and a detectable tag in contact with the crosslinking agent, first biocompatible polymer, the ligand or a combination thereof. |
| Claim: | 5. A cartilage targeting probe to treat damaged cartilage by increasing chondrogenic differentiation, wherein the cartilage targeting probe comprises: a biocompatible hyaluronic acid polymer crosslinked by a vinyl sulfone crosslinking agent to form a crosslinked biopolymer, wherein the biocompatible hyaluronic acid polymer has a molecular weight of 10K to 1.5M and the crosslinking ratio of the biocompatible polymer:crosslinking agent is between 4:1 and 1:4 and the crosslinked biopolymer has a diameter of about 200 to 500 nm to modulate internalization; a ligand in contact with the crosslinked biopolymer, wherein the ligand interacts with one or more cell surface targets; one or more TGF active agents selected from TGF-β1 and TGF-β3 associated with the polymer targeting probe, wherein the one or more TGF active agents are released to trigger higher chondrogenic differentiation; and a detectable tag in contact with the crosslinking agent, first biocompatible polymer, the ligand or a combination thereof, wherein the probe triggers stem cell recruitment, differentiation, and cartilage regeneration. |
| Claim: | 6. The arthritic cartilage targeting probe of claim 1 , wherein the ligand is hyaluronic acid and the one or more cell surface targets is a CD44 receptor. |
| Claim: | 7. The arthritic cartilage targeting probe of claim 1 , wherein the ligand is a folic acid and the one or more cell surface targets is a folate receptor. |
| Claim: | 8. The arthritic cartilage targeting probe of claim 1 , wherein the damaged cartilage is from mechanical trauma, physical trauma compression trauma, arthritic damage, inflammatory damage or a combination thereof. |
| Claim: | 9. The arthritic cartilage targeting probe of claim 1 wherein the molecular weight is about 10K, 60K, 700k, 1.5M or incremental variations thereof. |
| Claim: | 10. The arthritic cartilage targeting probe of claim 1 , wherein the crosslinking ratio is 1:4, 1:3, 1:2, 1:1, 1:3.9, 1:3.5, 1:2.3, 4:1, 3:1, 2:1 and incremental variations thereof. |
| Claim: | 11. The arthritic cartilage targeting probe of claim 1 , wherein the detectable tag is a fluorescent dye, a radioactive tag, a metal, a nanoparticle or a combination thereof. |
| Claim: | 12. The arthritic cartilage targeting probe of claim 1 , wherein the polymer targeting probe is biodegradable. |
| Claim: | 13. The arthritic cartilage targeting probe of claim 4 , wherein the one or more chemokines or one or more TGF active agents are bound to the crosslinked biopolymer, releasably associated, disposed in the crosslinked biopolymer, spray coated on the crosslinked biopolymer or a combination thereof. |
| Claim: | 14. The arthritic cartilage targeting probe of claim 4 wherein the crosslinked biopolymer comprises one or more pores and the one or more chemokines or one or more TGF active agents are disposed in the one or more pores for extended release over time. |
| Claim: | 15. The arthritic cartilage targeting probe of claim 14 , wherein the one or more pores have a diameter of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 nm or less than 1 nm or greater than 29 nm. |
| Claim: | 16. The arthritic cartilage targeting probe of claim 1 , wherein the polymer targeting probe contacts the one or more targets in less than 15 minutes to allow the quick detection within 15 minutes. |
| Claim: | 17. The arthritic cartilage targeting probe of claim 1 , the polymer targeting probe is intra-articular injected. |
| Claim: | 18. The arthritic cartilage targeting probe of claim 1 , wherein the targeting probe is used to image the damaged/injured cartilage and deliver one or more active agents to the damaged/injured cartilage. |
| Claim: | 19. A damaged/injured cartilage imaging probe for use as a medicament to target and/or treat damaged cartilage, wherein the damaged cartilage imaging probe comprises a biocompatible hyaluronic acid polymer crosslinked by a vinyl sulfone to form a crosslinked biopolymer, wherein the biocompatible hyaluronic acid polymer has a molecular weight of 10K to 1.5M and the crosslinking ratio of the biocompatible HA polymer:vinyl sulfone is between 4:1 and 1:4 and the crosslinked biopolymer has a diameter of about 200 to 500 nm to modulate internalization; a ligand in contact with the crosslinked biopolymer, wherein the ligand is hyaluronic acid that interacts with a CD44 receptor, folic acid that interacts with a folate receptor or both; and a detectable tag in contact with the crosslinking agent, first biocompatible polymer, the ligand or a combination thereof, wherein the detectable tag can be detected at the damaged cartilage and used to generate an image of the damaged cartilage, wherein the probe triggers stem cell recruitment, differentiation, and cartilage regeneration. |
| Claim: | 20. A damaged cartilage probe for use as a medicament for targeted treatment of damaged cartilage, wherein the damaged cartilage probe comprises: a cartilage damaged imaging probe for identifying damaged cartilage, wherein the cartilage damaged imaging probe comprises a biocompatible hyaluronic acid polymer crosslinked by a vinyl sulfone to form a crosslinked biopolymer, wherein the biocompatible hyaluronic acid polymer has a molecular weight of 10K to 1.5M and the crosslinking ratio of the biocompatible HA polymer:vinyl sulfone is between 4:1 and 1:4 and the crosslinked biopolymer has a diameter of about 200 to 500 nm to modulate internalization; a ligand in contact with the crosslinked biopolymer, wherein the ligand is hyaluronic acid that interacts with a CD44 receptor, folic acid that interacts with a folate receptor or both; and a detectable tag in contact with the crosslinking agent, first biocompatible polymer, the ligand or a combination thereof, wherein the detectable tag can be detected at the damaged cartilage and used to generate an image of the damaged cartilage; and a cartilage targeting probe for use as a medicament to treat damaged cartilage by recruiting stem cells, chondrocytes or both to the damaged cartilage, wherein the cartilage targeting probe comprises: a biocompatible hyaluronic acid polymer crosslinked by a vinyl sulfone crosslinking agent to form a crosslinked biopolymer, wherein the biocompatible hyaluronic acid polymer has a molecular weight of 10K to 1.5M and the crosslinking ratio of the biocompatible polymer:crosslinking agent is between 4:1 and 1:4 and the crosslinked biopolymer has the diameter of about 200 to 500 nm to modulate internalization; a ligand in contact with the crosslinked biopolymer, wherein the ligand interacts with one or more cell surface targets; one or more chemokines selected from SDF 1, SDF 1β, Epo, CCL2, CCL16, VEGF, TGF-β1 and TGF-β3, associated with the polymer targeting probe, wherein the one or more chemokines are released to recruit stem cells, chondrocytes or both; and optionally a second detectable tag in contact with the crosslinking agent, first biocompatible polymer, the ligand or a combination thereof; and optionally a chondrogenic differentiation probe for use as a medicament to treat damaged cartilage by increasing chondrogenic differentiation, wherein the chondrogenic differentiation probe comprises: a biocompatible hyaluronic acid polymer crosslinked by a vinyl sulfone crosslinking agent to form a crosslinked biopolymer, wherein the biocompatible hyaluronic acid polymer has a molecular weight of 10K to 1.5M and the crosslinking ratio of the biocompatible polymer:crosslinking agent is between 4:1 and 1:4 and the crosslinked biopolymer has a diameter of greater than about 200 nm to modulate internalization; a ligand in contact with the crosslinked biopolymer, wherein the ligand interacts with one or more cell surface targets; one or more TGF active agents selected from TGF-β1 and TGF-β3 associated with the polymer targeting probe, wherein the one or more TGF active agents are released to trigger higher chondrogenic differentiation; and a third detectable tag in contact with the crosslinking agent, first biocompatible polymer, the ligand or a combination thereof, wherein the probe triggers stem cell recruitment, differentiation, and cartilage regeneration. |
| Patent References Cited: | 9017644 April 2015 Baker, Jr. et al. 2008/0031850 February 2008 Bader 2011/0256628 October 2011 Galperin et al. 2012/0128741 May 2012 Gravett et al. 103690971 February 2014 2001231401 August 2001 2007517001 June 2007 2009544690 December 2009 2011506734 March 2011 2007098770 September 2007 2009077620 June 2009 WO-2009077399 June 2009 2012145439 October 2012 2013027854 March 2015 2017062493 April 2017 2017062493 April 2017 |
| Other References: | United States Patent and Trademark Office, International Search Report and Written Opinion for PCT/US2016/055552 dated Jan. 9, 2017, 14 pp. cited by applicant Ibrahim, et al., “The Impact of HA Oligomer Content on Physical, Mechanical, and Biologic Properties of Divinyl Sulfone-Crosslinked HA Hydrogels,” J. Biomed. Mater. Res. A., vol. 94(2), Aug. 2010, pp. 355-370. cited by applicant Shimojo, et al., “The Performance of Crosslinking with Divinyl Sulfone as Controlled by the Interplay Between the Chemical Modification and Conformation of Hyaluronic Acid,” J. Braz. Chem. Soc., vol. 26, No. 3, 2015, pp. 506-512. cited by applicant Baker, David W., et al., “Development of optical probes for in vivo imaging of polarized macrophages during foreign body reactions,” Acta Biomaterialia, vol. 10, Apr. 13, 2014, pp. 2945-2955. cited by applicant Chen, Wei-Tsung, et al., “Arthritis imaging using a near-infrared fluorescence folate-targeted probe,” Arthritis Res. & Ther., vol. 7 No. 2 Jan. 14, 2005, pp. R310-R317. cited by applicant Fani, M., et al., “In Vivo Imaging of Folate Receptor Positive Tumor Xenografts Using Novel Ga-NODAGA-Folate Conjugates,” Molecurlar Pharmaceutics, vol. 9, Apr. 12, 2012, pp. 1136-1145. cited by applicant Huang, Peng, et al., “Folic acid-conjugated Silica-modified gold nanorods for X-ray/CT imaging-guided dual-mode radiation and photo-thermal therapy,” Biomaterials, vol. 32, Sep. 13, 2011, pp. 9796-9809. cited by applicant Li, J., et al., “Polyethyleneimine-mediated synthesis of folic acid-targeted iron oxide nanoparticles for in vivo tumor MR maging,” Biomaterials, 34, Aug. 7, 2013, pp. 8382-8392. cited by applicant Zhou, Jun, et al., “In vivo evaluation of medical device-associated inflammation using a macrophage-specific positron emission tomography (PET) imaging proble,” Bioorganic & Medicinal Chemistry Letters, vol. 23, Feb. 13, 2013, pp. 2044-2047. cited by applicant Zhou, Jun, et al., “Real time monitoring of biomaterial-mediated inflammatory responses via macrophage-targeting NIR nanoprobes,” Biomaterials, vol. 32, Sep. 3, 2011, pp. 9383-9390. cited by applicant Zhou, Min, et al., “A Chelator-Free Multifunction [64Cu]CuS Nanoparticle Platform for simultaneous Micro-PET/CT Imaging and Photothermal Ablation Therapy,” JACS vol. 132, Oct. 13, 2010, pp. 15351-15358. cited by applicant Zhou, Min, et al., “Theranostic CuS nanoparticles targeting folate receptors for PET image-guided photothermal therapy,” J. Mater. Chem. B., vol. 3, Oct. 19, 2015, pp. 8939-8948. cited by applicant Borzachhiello, A., et al., “Hyaluronic Acid Based Hydrogels for Regenerative Medicine Applications,” BioMed Research International, Mar. 6, 2015, 12 pp. cited by applicant Fakhari, A., et al., “Applications and Emerging Trends of Hyaluronic Acid in Tissue Engineering, as a Dermal Filler, and in Osteoarthritis Treatment,” Acta Biomater, Jul. 2013, vol. 9(7), pp. 7081-7092. cited by applicant Fakhari, A., Dissertation entitled “Biomedical Application of Hyaluronic Acid Nanoparticles,” submitted to Bioengineering of University of Kansas and Defended Jan. 19, 2012, 154 pp. cited by applicant Ibrahim, S., et al., “The Impact of HA Oligomer Content on Physical, Mechanical, and Biologic Properties of Divinyl Sulfone-Crosslinked HA Hydrogels,” J. Biomed. Mater. Res. A., vol. 94(2), Aug. 2010, pp. 355-370. cited by applicant International Search Report and Written Opinion of the United States Patent and Trademark Office for PCT/US2016/055552 dated Jan. 9, 2017, 14 pp. cited by applicant Lai, Jui-Yang, “Relationship between structure and cytocompatibility of divinyl sulfone cross-linked hyaluronic acide,” Carbohydrate Polymers, Sep. 25, 2013, vol. 101, pp. 203-212. cited by applicant Shimojo, A.A.M., et al., “The Performance of Crosslinking with Divinyl Sulfone as Controlled by the Interplay Between the Chemical Modification and Conformation of Hyaluronic Acid,” J. Braz. Chem. Soc., vol. 26, No. 3, 2015, pp. 506-512. cited by applicant Xu, X., et al., “Heparin-decorated, hyaluronic acid-based hydrogel particles for the controlled release of bone morphogenetic protein 2,” Acta Biomaterialia, Apr. 24, 2011, vol. 7, pp. 3050-3059. cited by applicant Yeom, et al., “Effect of Cross-Linking Reagents for Hyaluronic Acid Hydrogel Dermal Fillers on Tissue Augmentation and Regeneration,” Bioconjugate Chem., Jan. 15, 2010, vol. 21, pp. 240-247. cited by applicant Yoon, H. Y., et al., “Tumor-targeting hyaluronic acid nanoparticles for photodynamic imaging and therapy,” Biomaterials, vol. 33, Feb. 24, 2012, pp. 3980-3989. cited by applicant Yu, Y., et al., “One-Step ‘Click’ Method for Generating Vinyl Sulfone Groups on Hydroxyl-Containing Water-Soluble Polymers,” BioMacromolecules, Jan. 9, 2012, vol. 13, pp. 937-942. cited by applicant Extended European Search Report of EP16854239.7 issued by the EPO on Sep. 14, 2018. cited by applicant Kato, Y., et al., “Accessibility of high molecular weight hyaluronan to articular cartilage and synovium,” Clinical Rheumatol. Vol. 21, Oct. 20, 2008, pp. 20-31. cited by applicant Rey-Rico, A., et al., “Adapted chondrogenic differentiation of human mesenchymal stem cells via controlled release of TGF-B1 from poly(ethylene oxide)-terephtalate/poly(butylene terepthalate) multiblock scaffolds,” Society for Biomaterials, Apr. 9, 2014, 14 pp. cited by applicant Turk, M.J., et al., “Folate-Targeted Imaging of Activated Macrophages in Rats with Adjuvant-Induced Arthritis,” Arthritis & Rheumatism, vol. 46, No. 7, Jul. 2002, pp. 1947-1955. cited by applicant Shcharbin, et al. “How to study dendrimers and dendriplexes III. Biodistribution, pharmacokinetics and toxicity in vivo” Journal of Controlled Release, Available online Mar. 4, 2014, 181 (2014) 40-52. cited by applicant Muller, et al. “Determination of Molecular Weight, Particle Size, and Density of High Number Generation PAMAM Dendrimers Using MALDI-TOF-MS and nES-GEMMA” Macromolecules 2007, 40, 5599-5605, Published on Web Jun. 20, 2007. cited by applicant Pradal, et al. “Effect of particle size on the biodistribution of nano- and microparticles following intra-articular injection in mice” International Journal of Pharmaceutics 498 (2016) 119-129, Available online Dec. 10, 2015. cited by applicant Naor, D., et al., “Review CD44 in rheumatoid arthritis,” Arthritis Res Ther, Feb. 28, 2003, 5:105-115. cited by applicant China National Intellectual Property Administration, Examination Report for China Patent Appl. No. 201680069894.7 dated Oct. 10, 2021, 23 pp. cited by applicant China National Intellectual Property Administration, 2nd Examination Report for China Patent Appl. No. 201680069894.7 dated Jul. 5, 2021, 23 pp. cited by applicant European Patent Office, Communication pursuant to Article 94(3) EPC for EP16854239.7 dated Jun. 3, 2019, 4 pp. cited by applicant European Patent Office, Communication pursuant to Article 94(3) EPC for EP16854239.7 dated Aug. 12, 2019, 5 pp. cited by applicant European Patent Office, Communication pursuant to Article 94(3) EPC for EP16854239.7 dated Nov. 18, 2019, 6 pp. cited by applicant European Patent Office, Communication pursuant to Article 94(3) EPC for EP16854239.7 dated Apr. 23, 2020, 4 pp. cited by applicant European Patent Office, Communication pursuant to Article 94(3) EPC for EP16854239.7 dated Jul. 14, 2020, 4 pp. cited by applicant European Patent Office, Communication pursuant to Article 94(3) EPC for EP16854239.7 dated Sep. 4, 2020, 5 pp. cited by applicant European Patent Office, Communication pursuant to Article 94(3) EPC for EP16854239.7 dated Feb. 17, 2020, 7 pp. cited by applicant Japan Patent Office, Notification of Refusal for Japan Appl. No. 2018-536714, Dated May 27, 2019, 13 pp. cited by applicant Japan Patent Office, Notification of Refusal for Japan Appl. No. 2018-536714, Dated Dec. 9, 2019, 13 pp. cited by applicant |
| Primary Examiner: | Dickinson, Paul W |
| Attorney, Agent or Firm: | Flores, Edwin S. Chalker, Daniel J. Chalker Flores, LLP |
| رقم الانضمام: | edspgr.12201700 |
| قاعدة البيانات: | USPTO Patent Grants |
| الوصف غير متاح. |